[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ryazan State Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100582233","myocardial-infarction-in-the-elderly-100582233",false,"NCT06860646","Myocardial Infarction in the Elderly","Hospital Registry of Patients with Myocardial Infarction in Individuals Aged 75 Years and Older","Inclusion Criteria:\n\n\\- age 75 years and older, presence of an established diagnosis of myocardial infarction at the time of hospitalization.\n\nExclusion Criteria:\n\n\\-","ALL","75 Years",{"count":19,"type":20},1000,"ESTIMATED","10 Years","OBSERVATIONAL","An observational registry study of patients aged 75 years and older with an established diagnosis of myocardial infarction, initiated in 2020, with an assessment of clinical, instrumental, demographic and prognostic data. Statistical analysis was performed using the StatTech v. 4.5.0 program (developer - StatTech LLC, Russia). Differences were considered statistically significant at p \\\u003C0.05.",[25],"Myocardial Infarction (MI)","RECRUITING","2025-02-28",{"date":29,"type":30},"2025-03-06","ACTUAL",{"date":32,"type":30},"2020-09-01",{"date":34,"type":20},"2030-12",{"name":36,"class":37},"Ryazan State Medical University","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":38},"100510998","efficacy-and-safety-of-the-regulatory-polypeptides-in-patients-with-peripheral-atherosclerosis-100510998","NCT05933720","Efficacy and Safety of the Regulatory Polypeptides in Patients With Peripheral Atherosclerosis.","Evaluation of the Efficacy and Safety of the Drug Based on Vascular Regulatory Polypeptides for the Treatment of Patients With Lower Extremity Atherosclerotic Arterial Occlusive Disease.","Inclusion Criteria:\n\nmen or women over 18 years of age with lower extremity atherosclerotic arterial occlusive disease, confirmed with instrumental work-up methods (ultrasonography or angiography).\n\nExclusion Criteria:\n\nmen or women under 18 years of age; history of anaphylaxis; hypersensitivity to any of the components that make up the drug Slavinorm®, and proteins of animal origin; absolute and relative contraindications to the treadmill test; failure to walk at a minimum speed of 3.2 km\u002Fh (2 mph) at a minimum treadmill angle for at least 2 minutes during the stress test during the screening phase; depression of the ST segment more than 1 mm in one or more standard leads on the electrocardiogram; peripheral artery disease not associated with atherosclerosis; patients who underwent reconstructive surgery or invasive interventions on the arteries of the lower extremities in history without a clinic of intermittent claudication; angina pectoris III-IV functional class (FC) according to the CCS classification; body mass index \\>35 kg\u002Fm2; acute or chronic renal (creatinine clearance less than 30 ml \u002F min) and \u002F or liver failure \\[aspartate aminotransferase (AST), alanine aminotransferase (ALT) \\> 3 times the upper limit of normal\\]; chronic heart failure III-IV FC according to NYHA; acute coronary syndrome within 6 months. before the start of the screening period; any clinically significant condition or comorbidity that, in the opinion of the Investigator, would preclude the patient from participating in the study.","18 Years","80 Years",{"count":49,"type":20},120,"INTERVENTIONAL",[52],"NA","The study is aimed at assessing the role of the activity of markers of endothelial dysfunction (cytotoxic malonic aldehyde (MDA), angiotensin II, endothelial nitric oxide synthase (NO), endothelin-1, prostacyclin) in the systemic circulation in patients with lower extremity atherosclerotic arterial occlusive disease undergoing open reconstructive interventions.",[55],"Peripheral Arterial Occlusive Disease",[57,58,59],"Peripheral Arterial Disease","bypass grafting","polypeptides","2023-06-27",{"date":62,"type":30},"2023-07-06",{"date":64,"type":30},"2023-04-01",{"date":66,"type":20},"2026-09-01",{"name":36,"class":37},""]